Dr Reddy's Labs gets USFDA EIR for IPDO facility
New Delhi: Dr. Reddy''s Laboratories on Thursday said the US health regulator has closed inspection of its Telangana-based facility.
The company has received the establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for Medchal-Malkajgiri-based integrated product development organization (IPDO) indicating closure of the audit, Dr. Reddy''s Laboratories said in a regulatory filing.
The USFDA issues an EIR to a company when an inspection is satisfactorily closed.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.